The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Recombinant DNA Technology Market Research Report 2025

Global Recombinant DNA Technology Market Research Report 2025

Publishing Date : Mar, 2025

License Type :

Report Code : 1805601

No of Pages : 91

Ask Your Query

Report Description
Table of Content

Synopsis

The global Recombinant DNA Technology market was valued at US$ 3023.5 million in 2023 and is anticipated to reach US$ 5388.6 million by 2030, witnessing a CAGR of 8.6% during the forecast period 2024-2030.

North American market for Recombinant DNA Technology is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

Asia-Pacific market for Recombinant DNA Technology is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The global market for Recombinant DNA Technology in Biotechnology and Pharmaceutical Companies is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.

The major global companies of Recombinant DNA Technology include Monsanto Company, Roche, Biogen, Amgen, Novartis, Eli Lilly and Company, GenScript, Pfizer Inc. and Novo Nordisk, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report aims to provide a comprehensive presentation of the global market for Recombinant DNA Technology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Recombinant DNA Technology.

Report Scope

The Recombinant DNA Technology market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Recombinant DNA Technology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Recombinant DNA Technology companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

By Company

Monsanto Company
Roche
Biogen
Amgen
Novartis
Eli Lilly and Company
GenScript
Pfizer Inc.
Novo Nordisk
Sanofi
Merck KGaA
Profacgen
Biocon
GlaxoSmithKline
Cibus
Horizon Discovery Group
New England Biolabs

Segment by Type

Therapeutic Agent
Vaccine
Biotech Crops
Specialty Chemicals

Segment by Application

Biotechnology and Pharmaceutical Companies
Academic & Government Research Institutes
Others

By Region

North America (United States, Canada)
Europe (Germany, France, U.K., Italy, Netherlands)
Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Recombinant DNA Technology companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Recombinant DNA Technology Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Therapeutic Agent
1.2.3 Vaccine
1.2.4 Biotech Crops
1.2.5 Specialty Chemicals
1.3 Market by Application
1.3.1 Global Recombinant DNA Technology Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Biotechnology and Pharmaceutical Companies
1.3.3 Academic & Government Research Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Recombinant DNA Technology Market Perspective (2019-2030)
2.2 Recombinant DNA Technology Growth Trends by Region
2.2.1 Global Recombinant DNA Technology Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Recombinant DNA Technology Historic Market Size by Region (2019-2024)
2.2.3 Recombinant DNA Technology Forecasted Market Size by Region (2025-2030)
2.3 Recombinant DNA Technology Market Dynamics
2.3.1 Recombinant DNA Technology Industry Trends
2.3.2 Recombinant DNA Technology Market Drivers
2.3.3 Recombinant DNA Technology Market Challenges
2.3.4 Recombinant DNA Technology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Recombinant DNA Technology Players by Revenue
3.1.1 Global Top Recombinant DNA Technology Players by Revenue (2019-2024)
3.1.2 Global Recombinant DNA Technology Revenue Market Share by Players (2019-2024)
3.2 Global Recombinant DNA Technology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Recombinant DNA Technology Revenue
3.4 Global Recombinant DNA Technology Market Concentration Ratio
3.4.1 Global Recombinant DNA Technology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Recombinant DNA Technology Revenue in 2023
3.5 Recombinant DNA Technology Key Players Head office and Area Served
3.6 Key Players Recombinant DNA Technology Product Solution and Service
3.7 Date of Enter into Recombinant DNA Technology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Recombinant DNA Technology Breakdown Data by Type
4.1 Global Recombinant DNA Technology Historic Market Size by Type (2019-2024)
4.2 Global Recombinant DNA Technology Forecasted Market Size by Type (2025-2030)
5 Recombinant DNA Technology Breakdown Data by Application
5.1 Global Recombinant DNA Technology Historic Market Size by Application (2019-2024)
5.2 Global Recombinant DNA Technology Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Recombinant DNA Technology Market Size (2019-2030)
6.2 North America Recombinant DNA Technology Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Recombinant DNA Technology Market Size by Country (2019-2024)
6.4 North America Recombinant DNA Technology Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Recombinant DNA Technology Market Size (2019-2030)
7.2 Europe Recombinant DNA Technology Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Recombinant DNA Technology Market Size by Country (2019-2024)
7.4 Europe Recombinant DNA Technology Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Recombinant DNA Technology Market Size (2019-2030)
8.2 Asia-Pacific Recombinant DNA Technology Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Recombinant DNA Technology Market Size by Region (2019-2024)
8.4 Asia-Pacific Recombinant DNA Technology Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Recombinant DNA Technology Market Size (2019-2030)
9.2 Latin America Recombinant DNA Technology Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Recombinant DNA Technology Market Size by Country (2019-2024)
9.4 Latin America Recombinant DNA Technology Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Recombinant DNA Technology Market Size (2019-2030)
10.2 Middle East & Africa Recombinant DNA Technology Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Recombinant DNA Technology Market Size by Country (2019-2024)
10.4 Middle East & Africa Recombinant DNA Technology Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Monsanto Company
11.1.1 Monsanto Company Company Detail
11.1.2 Monsanto Company Business Overview
11.1.3 Monsanto Company Recombinant DNA Technology Introduction
11.1.4 Monsanto Company Revenue in Recombinant DNA Technology Business (2019-2024)
11.1.5 Monsanto Company Recent Development
11.2 Roche
11.2.1 Roche Company Detail
11.2.2 Roche Business Overview
11.2.3 Roche Recombinant DNA Technology Introduction
11.2.4 Roche Revenue in Recombinant DNA Technology Business (2019-2024)
11.2.5 Roche Recent Development
11.3 Biogen
11.3.1 Biogen Company Detail
11.3.2 Biogen Business Overview
11.3.3 Biogen Recombinant DNA Technology Introduction
11.3.4 Biogen Revenue in Recombinant DNA Technology Business (2019-2024)
11.3.5 Biogen Recent Development
11.4 Amgen
11.4.1 Amgen Company Detail
11.4.2 Amgen Business Overview
11.4.3 Amgen Recombinant DNA Technology Introduction
11.4.4 Amgen Revenue in Recombinant DNA Technology Business (2019-2024)
11.4.5 Amgen Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Recombinant DNA Technology Introduction
11.5.4 Novartis Revenue in Recombinant DNA Technology Business (2019-2024)
11.5.5 Novartis Recent Development
11.6 Eli Lilly and Company
11.6.1 Eli Lilly and Company Company Detail
11.6.2 Eli Lilly and Company Business Overview
11.6.3 Eli Lilly and Company Recombinant DNA Technology Introduction
11.6.4 Eli Lilly and Company Revenue in Recombinant DNA Technology Business (2019-2024)
11.6.5 Eli Lilly and Company Recent Development
11.7 GenScript
11.7.1 GenScript Company Detail
11.7.2 GenScript Business Overview
11.7.3 GenScript Recombinant DNA Technology Introduction
11.7.4 GenScript Revenue in Recombinant DNA Technology Business (2019-2024)
11.7.5 GenScript Recent Development
11.8 Pfizer Inc.
11.8.1 Pfizer Inc. Company Detail
11.8.2 Pfizer Inc. Business Overview
11.8.3 Pfizer Inc. Recombinant DNA Technology Introduction
11.8.4 Pfizer Inc. Revenue in Recombinant DNA Technology Business (2019-2024)
11.8.5 Pfizer Inc. Recent Development
11.9 Novo Nordisk
11.9.1 Novo Nordisk Company Detail
11.9.2 Novo Nordisk Business Overview
11.9.3 Novo Nordisk Recombinant DNA Technology Introduction
11.9.4 Novo Nordisk Revenue in Recombinant DNA Technology Business (2019-2024)
11.9.5 Novo Nordisk Recent Development
11.10 Sanofi
11.10.1 Sanofi Company Detail
11.10.2 Sanofi Business Overview
11.10.3 Sanofi Recombinant DNA Technology Introduction
11.10.4 Sanofi Revenue in Recombinant DNA Technology Business (2019-2024)
11.10.5 Sanofi Recent Development
11.11 Merck KGaA
11.11.1 Merck KGaA Company Detail
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Recombinant DNA Technology Introduction
11.11.4 Merck KGaA Revenue in Recombinant DNA Technology Business (2019-2024)
11.11.5 Merck KGaA Recent Development
11.12 Profacgen
11.12.1 Profacgen Company Detail
11.12.2 Profacgen Business Overview
11.12.3 Profacgen Recombinant DNA Technology Introduction
11.12.4 Profacgen Revenue in Recombinant DNA Technology Business (2019-2024)
11.12.5 Profacgen Recent Development
11.13 Biocon
11.13.1 Biocon Company Detail
11.13.2 Biocon Business Overview
11.13.3 Biocon Recombinant DNA Technology Introduction
11.13.4 Biocon Revenue in Recombinant DNA Technology Business (2019-2024)
11.13.5 Biocon Recent Development
11.14 GlaxoSmithKline
11.14.1 GlaxoSmithKline Company Detail
11.14.2 GlaxoSmithKline Business Overview
11.14.3 GlaxoSmithKline Recombinant DNA Technology Introduction
11.14.4 GlaxoSmithKline Revenue in Recombinant DNA Technology Business (2019-2024)
11.14.5 GlaxoSmithKline Recent Development
11.15 Cibus
11.15.1 Cibus Company Detail
11.15.2 Cibus Business Overview
11.15.3 Cibus Recombinant DNA Technology Introduction
11.15.4 Cibus Revenue in Recombinant DNA Technology Business (2019-2024)
11.15.5 Cibus Recent Development
11.16 Horizon Discovery Group
11.16.1 Horizon Discovery Group Company Detail
11.16.2 Horizon Discovery Group Business Overview
11.16.3 Horizon Discovery Group Recombinant DNA Technology Introduction
11.16.4 Horizon Discovery Group Revenue in Recombinant DNA Technology Business (2019-2024)
11.16.5 Horizon Discovery Group Recent Development
11.17 New England Biolabs
11.17.1 New England Biolabs Company Detail
11.17.2 New England Biolabs Business Overview
11.17.3 New England Biolabs Recombinant DNA Technology Introduction
11.17.4 New England Biolabs Revenue in Recombinant DNA Technology Business (2019-2024)
11.17.5 New England Biolabs Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business:

Since 2015

Pre Sales Support:

24*7

Post Sales Support:

24*7

Turn Around Time:

Usually 2 Hours

Clients Served:

425 and counting

Clients Assisted:

1750 and counting

Client Types:

Govt Projects, Private Companies, Consultant and Individuals

Payment:

Partners with:

Number of reports:

1,000,000 and counting

Custom Research:

Available

Report Availability:

Global and Regional Reports

Report Delivery Format:

Usually PDF

Security:

Latest Life Science Market Reports

Global Support Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Global Hospital OT and X-Ray, Cathode Room Doors (Hermetically Sealed Door) Market Research Report 2025

Global Children\'s DHA Market Research Report 2025

Global Marine Derived Drugs Market Research Report 2025

Global Glucagon Like Peptide-1 (GLP-1) Agonists Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

Payments Accepted From

Connect with us at

Complete Secure Website

#socialicons>a span { top: 0px; left: -100%; -webkit-transition: all 0.3s ease; -moz-transition: all 0.3s ease-in-out; -o-transition: all 0.3s ease-in-out; -ms-transition: all 0.3s ease-in-out; transition: all 0.3s ease-in-out;} #socialicons>ahover div{left: 0px;}